List view / Grid view
22 January 2016 | By Victoria White
The research from Georgia State University scientists provides strong translational potential with respect to biomarkers that play critical roles in the development of endometrial/lung tumours...
21 January 2016 | By Hans Fliri PhD, Chairman, Cypralis
Here, Dr Hans Fliri, Chairman and CEO of Selcia and Chairman of Cypralis, presents a strong case for targeting mitochondrial cyclophilin D to prevent progression of chronic neurodegenerative diseases...
21 January 2016 | By Victoria White
The Lead Discovery Centre (LDC) and Roche have announced that they are to collaborate to identify and leverage innovative therapeutic opportunities that address diseases of unmet medical need...
20 January 2016 | By Victoria White
Through the Phenotypic Discovery Initiative (PDi), partners will build robust, disease-relevant phenotypic assays with a focus on human-derived systems with the aim of identifying new drug targets and hit molecules.
20 January 2016 | By Victoria White
Researchers made B-cells sense they were starving by using the drug Rapamycin, enabling them to turn the senescence of EBV-infected cells on and off...
19 January 2016 | By Philippe Villain-Guillot, CEO, Nosopharm
Philippe Villain-Guillot, CEO, Nosopharm, discusses antimicrobial resistance and the challenges facing antibacterial drug discovery and development...
19 January 2016 | By Victoria White
The largest analysis of breast cancer cell function to date suggests dozens of new uses for existing drugs, new targets for drug discovery, and new drug combinations...
18 January 2016 | By Victoria White
Centuari has also announced that it has appointed Dr Clive Dix as Chairman and secured the first tranche of a £3M raise to develop its first lead candidate...
13 January 2016 | By Oxford Global
Oxford Global Conferences are proud to present the successful 17th Annual Drug Discovery Leaders Summit and co-located 4th Annual Discovery Chemistry & Drug Design Congress taking place on the 13th & 14th June in Berlin...
13 January 2016 | By Victoria White
NIAID has awarded $5 million in funding for 24 research projects to help address the growing health threat of antibiotic resistance...
13 January 2016 | By Victoria White
Boehringer Ingelheim and Arena Pharmaceuticals have signed an exclusive agreement to conduct joint research to identify drug candidates for psychiatric diseases...
12 January 2016 | By Victoria White
The acquisition includes IOmet's comprehensive preclinical pipeline of IDO (indoleamine-2,3-dioxygenase 1), TDO (tryptophan-2,3-dioxygenase), and dual-acting IDO/TDO inhibitors...
12 January 2016 | By Victoria White
ReNeuron is researching the therapeutic potential of exosomes derived from its proprietary stem cell lines. The Company is also exploring the potential of its exosomes as a delivery system for gene therapy treatments...
11 January 2016 | By Victoria White
The collaboration will focus on the development of drugs targeting important human oncogenes, including RAS, and new antibiotics targeting Gram-negative bacteria...
11 January 2016 | By Victoria White
The agreement gives Novartis access to four preclinical programmes that target regulatory T-cell populations, inhibitory cytokines, and immunosuppressive metabolites in the tumour microenvironment...
